Your browser doesn't support javascript.
loading
Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide.
Lodi, Alessia; Pandey, Renu; Chiou, Jennifer; Bhattacharya, Ayon; Huang, Shiliang; Pan, Xingxin; Burgman, Brandon; Yi, S Stephen; Tiziani, Stefano; Brenner, Andrew J.
Afiliación
  • Lodi A; Department of Nutritional Sciences, The University of Texas at Austin, Austin, TX, United States.
  • Pandey R; Dell Pediatric Research Institute, Dell Medical School, The University of Texas at Austin, Austin, TX, United States.
  • Chiou J; Department of Nutritional Sciences, The University of Texas at Austin, Austin, TX, United States.
  • Bhattacharya A; Dell Pediatric Research Institute, Dell Medical School, The University of Texas at Austin, Austin, TX, United States.
  • Huang S; Department of Nutritional Sciences, The University of Texas at Austin, Austin, TX, United States.
  • Pan X; Dell Pediatric Research Institute, Dell Medical School, The University of Texas at Austin, Austin, TX, United States.
  • Burgman B; Mays Cancer Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.
  • Yi SS; Mays Cancer Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.
  • Tiziani S; Department of Oncology, Dell Medical School, Livestrong Cancer Institutes, The University of Texas at Austin, Austin, TX, United States.
  • Brenner AJ; Department of Oncology, Dell Medical School, Livestrong Cancer Institutes, The University of Texas at Austin, Austin, TX, United States.
Front Oncol ; 12: 900082, 2022.
Article en En | MEDLINE | ID: mdl-36226069

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos